AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference

  AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference

Leerink Swann 2014 Global Healthcare Conference

Business Wire

WEST CHESTER, Ohio -- January 20, 2014

AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device
provider, today announced that it will present at the Leerink Swann 2014
Global Healthcare Conference at the Waldorf Astoria Hotel in New York on
Wednesday, February 12, 2014. Management is scheduled to present at11:30 a.m.
Eastern Time.

A live audio webcast and replay of the presentation will be available for 30
days following the presentation at www.atricure.com.

About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Contact:

AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
awade@atricure.com
or
Investor Relations Contact
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com